Trial Profile
Phase II study of O6-benzylguanine [benzylguanine] and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas or progressive brain stem tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
- Indications Brain cancer; Glioma
- Focus Therapeutic Use
- 10 Aug 2011 Planned end date changed from 1 Jul 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 10 Aug 2011 Planned end date changed from 1 Jul 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 08 Jun 2010 Planned end date changed from 1 May 2007 to 1 Jul 2010 as reported by ClinicalTrials.gov.